Next Green Wave Achieves Operational Milestones For Intrexon’s Botticelli(TM) Cannabis Plantlet Production
Next Green Wave Holdings Inc. (CSE:NGW, OTCQX:NXGWF) (“Next Green Wave”, “NGW” or the “Company”) announces that it has completed the installation and activation of its research and innovation laboratory under license from biotech leader Intrexon (NASDAQ: XON). Under the agreement, these milestones will advance Intrexon’s Botticelli™ next generation plant (non-GMO) propagation platform and begin the rapid optimization and production of Next Green Wave’s proprietary cannabis cultivars.
Per their agreement announced on March 22, 2019, Intrexon and NGW have achieved the following milestones:
- Optimization of Botticelli™ protocol for Next Green Wave’s hemp CBD strains.
- Completion of tissue culture lab at NGW production site to begin Botticelli™ optimization of NGW’s proprietary nursery stock.
Figure 1: Botticelli™ laboratory at NGW facility
“The opening of this research facility is a huge milestone on our path to establish a world-class cannabis nursery. Combining Intrexon’s proprietary Botticelli™ tissue culture platform with NGW’s proprietary stock and cultivation team, we aim to push the limits of the current cannabis performance paradigm. After a successful optimization phase, we will begin the Botticelli™ plantlet production for our own internal cultivation and also supply our industry leading plantlets to other licensed cultivators in California,” stated Michael Jennings, CEO of NGW.
In the U.S. market, legal cannabis revenue is projected to exceed $31.3 billion by 2022*, with California representing around a third of that market. Current cannabis cultivation is predominantly dependent on clonal propagation by using cuttings of mother plants. This creates barriers to meeting product demand and also risk of disease susceptibility. In addition, plants derived from repeated cuttings lose vigor in performance. Botticelli™ offers potential for a sustainable, scalable, and more economical solution than conventional clones.
“We are excited to have achieved optimization of Botticelli™ protocol for hemp CBD strains, as a proxy for cannabis, and feel confident about the potential of our platform for cannabis cultivation. We are looking forward to seeing the Botticelli™ platform enabled and integrated with NGW’s production, validating its value-add for the cannabis industry,” commented Sekhar Boddupalli, President, Intrexon’s Ag Bio Division.
NGW is also pleased to announce that its current nursery production, derived using traditional cloning methods, has reached inventory levels sufficient to begin sales to other retail and licensed producers. The nursery has the capacity to produce up to 80,000 plantlets per month to fulfill both internal use and external sales. Additionally, the company has now completed its second harvest of a variety of premium cannabis flower and entered a perpetual cycle to harvest two rooms every 10-14 days.
About Next Green Wave
NGW is a fully integrated premium cannabis producer with 8 legacy brands and over 45 products through its subsidiary WEARESDC. Based in Coalinga, California the company owns and operates a state-of-the-art cultivation facility and is currently expanding operations on the cannabis zoned property it is situated on. NGW has a seed library of over 120 strains which include multiple award-winning genetics and cultivars and is developing its nursery cloning operations with bio-tech leader Intrexon. To find out more visit us at www.nextgreenwave.com or follow us on Twitter, Instagram, or LinkedIn.
* Source: Arcview Market Research Group
On behalf of the board,
Michael Jennings, CEO
Next Green Wave Holdings Inc.
For more information regarding Next Green Wave, contact:
VP Corp. Development
Tel: +1 (778) 589-2848
Next Green Wave Forward Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, the risk factors included in the preliminary prospectus, including without limitation dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete construction of its proposed facilities in a timely manner; engaging in activities which currently are illegal under US federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; NGW’s limited operating history and lack of historical profits; reliance on management; NGW’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, including closing of Tranche 1 and Tranche 2 of the Notes; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. Readers are encouraged to the review the section titled “Risk Factors” in NGW’s prospectus. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although NGW has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. NGW no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.
In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.
Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.
The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement
Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination
Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that as part of the equity fundraise announced yesterday, Antony Calamita and Andrew Male, Directors of the Company, subscribed for 285,714 Ordinary Shares and 1,428,571 Ordinary Shares respectively. The subscriptions are at a price of 3.5 pence per ordinary share for a total of £60,000. Following these subscriptions, Antony Calamita is now interested in 54,385,714 Ordinary Shares, representing 8.61% of the Company’s share capital as increased by the fundraising, and Andrew Male is now interested in 6,138,196 Ordinary Shares, representing 0.97% of the Company’s issued share capital as increased by the fundraising
Further, the timetable for receipt of applications under the Broker Option, which was also announced yesterday, has been extended until 5:00 pm 9 April 2021 to capture additional interest which was unable to be completed yesterday.
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.
In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders.
Gage Cannabis Announces Exclusive Partnership With Blue River to Bring Award-Winning Cannabis Extracts to Michigan
Gage Growth Corp. (“Gage” or the “Company”) (CSE:GAGE), a leading high-quality craft cannabis brand and operator in Michigan, announced today that it has signed an agreement with Blue River™ Extracts & Terpenes (“Blue River™”) to bring the brand’s award-winning solventless technology and other trademark branded products to the state’s medical patients and cannabis consumers. The Company will have exclusive rights to Blue River™’s premium product offerings in Michigan.